Federal Advocacy / Issues / Legislation
Join in the effort to promote the Federal Patient Access to Pharmacist's Services. Take action
Community pharmacy advocacy and issues at the national level with NCPA. Read more
Health-system pharmacy advocacy and issues at the federal level with Find out more.
Click here for contact information to Montana's Congressional Delegation
Email, phone, fax and mailing address for US Representative Ryan Zinke, Senator Steve Daines and Senator Jon Tester.
NCPA’s Advocacy Report provides a weekly detailed summary of recent and breaking legislative, regulatory and state developments impacting independent community pharmacy, and NCPA efforts to effect policies to benefit its membership and the industry. The weekly report is distributed to NCPA leadership, key committees, allied organizations / stakeholders and major contributors to the NCPA LDF and PAC.
Week Ending April 22, 2017
You Can Still Join the Fight Against PBMs. Come to D.C for the Congressional Fly-In April 26 & 27: Emails, phone calls, and faxes to your elected officials in Washington can get their attention, but face-to-face meetings carry the greatest weight. We need YOU to share your story about PBM abuses against your patients and your business on Capitol Hill next week during the NCPA Congressional Pharmacy Fly-In April 26-27.
Week Ending April 15, 2017
Specialty Rxs Require a Special Dispensing Fee Pharmacy Groups Tell CMS: Concerned that states may not fully cover the cost of acquiring and dispensing Medicaid specialty drugs, NCPA, NACDS and the National Association of Specialty Pharmacy (NASP) wrote to CMS this week, seeking a meeting. Read the complete weekly report.
Week Ending April 8, 2017
Medicare Pharmacy Choice and Access House Bill Introduced This Week: The Ensuring Seniors Access to Local Pharmacies Act, H.R. 1939, was introduced by Reps. Morgan Griffith (R-VA) and Peter Welch (D-VT) on April 5th. The bill would allow community pharmacies in medically underserved areas to participate in Medicare Part D preferred pharmacy networks if they can meet the terms and conditions the networks require. Read the complete weekly report --- and note Montana's mention at the end of the report.
Week Ending April 1, 2017
118 Health Care Groups Support Bills Banning Retroactive Pharmacy DIR Fees: In a strong display of unity, 118 health care organizations have signed on to letters supporting companion bills in the Senate and House of Representatives – S. 413/H.R. 1038, the Improving Transparency and Accuracy in Medicare Part D Drug Spending Act – that would prohibit retroactive pharmacy direct and indirect remuneration (DIR) fees in the Medicare Part D program. Read the complete weekly report.
Week Ending March 25, 2017
Come Give Congress a Piece of Your Mind at the Congressional Pharmacy Fly-In April 26-27: We are filling the halls of Congress April 26-27 with independent community pharmacies who are passionate about their patients and their practice and are tired of the tyranny of PBMs. Join your colleagues as we take on Capitol Hill during the NCPA Congressional Pharmacy Fly-In to educate elected officials in person about PBMs’ abusive practices and urge them to stand up for community pharmacy. Read the complete weekly report. Senate thank you letter. House thank you letter.
Week Ending March 11, 2017
Bill Recognizing Pharmacists as Health Care Providers Continues to Gain Momentum: S. 109/H.R. 592, the Pharmacy and Medically Underserved Areas Enhancement Act continues to gain sponsors. The bill recognizes pharmacists as health care providers and permits state-licensed pharmacists in medically underserved communities to both provide and be reimbursed for an expanded scope of patient-care services under the Medicare Part B program. Read all articles in the report.
Week Ending March 4, 2017
Generic Drug Payment Bill Introduced in the U.S. House of Representatives: Bipartisan legislation to increase transparency in generic drug payments in taxpayer-funded federal health programs and preserve patient access to local community pharmacies was introduced in the House this week by Reps. Doug Collins (R-Ga.) and Dave Loebsack (D-Iowa) along with six of their colleagues. H.R. 1316, the Prescription Drug Price Transparency Act... Read the full report.
Related articles -- Generic Drug Pricing Transparency and Statement for the Record.
Week Ending February 25, 2017
NCPA Hosts DIR Stakeholder Call: This week NCPA hosted a call with industry partners providing an update on recent developments regarding NCPA’s efforts on pharmacy DIR fees. Click here for highlights of the briefing and the full report.
Week Ending February 18, 2017
House/Senate DIR Bills Introduced: This week, Reps. Morgan Griffith (R-Va.) and Peter Welch (D-Vt.), along with 16 of their colleagues, introduced H.R. 1038, the "Improving Transparency and Accuracy in Medicare Part D Drug Spending Act," that would prohibit retroactive pharmacy DIR fees. The bill was introduced with very strong support ...Read the full report.
Week Ending February 11, 2017
NCPA Responds to PBM Efforts to Limit Potential Reforms: An apparently leaked memorandum has surfaced from Mark Merritt, president and CEO of the Pharmaceutical Care Management Association (PCMA), to the association's board of directors. It outlines PCMA's strategies to mitigate possible reforms of PBMs. NCPA responded to news surrounding the leaked memo by stressing the untold profits PBMs have extracted from patients, drug manufacturers and health plans, with very little oversight and almost no transparency. Read the full report.
Week Ending February 4, 2017
Sen. Brown Submits DIR Fees Question as part of Senate Finance Committee Confirmation Hearing for HHS Nominee: Rep. Tom Price (R-Ga.), President Trump's nominee to lead the Department of Health and Human Services (HHS) testified last week before the Senate Finance Committee. At NCPA’s request, independent pharmacy champion Sen. Sherrod Brown (D-OH) submitted a question on DIR fees and pending CMS guidance for the record and Rep. Price has subsequently provided an answer. Read the full report.